DeepMed Research

Pharmacyclics LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: 607

Market Cap: -

Website: http://www.pharmacyclics.com

Clinical Trials

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Diffuse Well-differentiated Lymphocytic Lymphoma
B Cell Lymphoma
Waldenstrom Macroglobulinemia
Small Lymphocytic Lymphoma
Follicular Lymphoma
Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma
Burkitt Lymphoma
B-Cell Diffuse Lymphoma

Interventions: Drug: PCI-32765

First Posted Date: 2010-04-22

Last Posted Date: 2020-05-27

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 199

Registration Number: NCT01109069

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Fletcher Allen Health Care and University of Vermont, Burlington, Vermont, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Small Lymphocytic Lymphoma
B-cell Chronic Lymphocytic Leukemia

Interventions: Drug: PCI-32765

First Posted Date: 2010-04-16

Last Posted Date: 2014-03-31

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 133

Registration Number: NCT01105247

Locations: 🇺🇸
Sarah Cannon, Nashville, Tennessee, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 7 locations

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Phase 2

Completed

Conditions: Pancreatic Cancer
Ductal Adrenocarcinoma
Exocrine Pancreatic Cancer

Interventions: Drug: PCI-27483
Drug: Gemcitabine

First Posted Date: 2009-11-25

Last Posted Date: 2014-04-24

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 42

Registration Number: NCT01020006

Locations: 🇺🇸
Park Nicollet Institute, St. Louis Park, Minnesota, United States
🇺🇸
Space Coast Medical Associates, Titusville, Florida, United States
🇺🇸
Columbia University, New York, New York, United States

and more 14 locations

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Phase 1

Completed

Conditions: B-Cell Lymphoma
B-Cell Leukemia

Interventions: Drug: PCI-32765

First Posted Date: 2009-02-24

Last Posted Date: 2013-05-22

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 66

Registration Number: NCT00849654

Locations: 🇺🇸
University of Texas, MD Anderson, Houston, Texas, United States
🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States
🇺🇸
National Cancer Institute, Bethesda, Maryland, United States

and more 6 locations

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Hodgkin Disease
Lymphoma, Non-Hodgkin

Interventions: Drug: PCI-24781

First Posted Date: 2008-07-30

Last Posted Date: 2014-04-07

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 55

Registration Number: NCT00724984

Locations: 🇺🇸
University of Vermont and Fletcher Allen Health Care, Burlington, Vermont, United States
🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 5 locations

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

Phase 1

Completed

Conditions: Neoplasms by Site
Lymphoma, Non-hodgkin
Hodgkin Disease
Multiple Myeloma
Leukemia, Lymphocytic, Chronic

Interventions: Drug: PCI-24781

First Posted Date: 2007-11-21

Last Posted Date: 2011-09-28

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 36

Registration Number: NCT00562224

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
California Cancer Care, Greenbrae, California, United States

and more 1 locations

Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients

Phase 1

Completed

Conditions: Hematologic Neoplasms
Neoplasms

First Posted Date: 2007-05-15

Last Posted Date: 2010-08-25

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 40

Registration Number: NCT00473577

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: Motexafin Gadolinium

First Posted Date: 2006-09-07

Last Posted Date: 2014-07-24

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 50

Registration Number: NCT00373204

Locations: 🇺🇸
Wilshire Oncology Medical Group, La Verne, California, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇷🇸
Clinic for Pulmonary Diseases, Belgrade, Serbia

and more 19 locations

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-Small Cell Lung Carcinoma

Interventions: Drug: Motexafin gadolinium and pemetrexed

First Posted Date: 2006-08-17

Last Posted Date: 2013-10-31

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 74

Registration Number: NCT00365183

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Leukemia
Lymphoma

First Posted Date: 2006-02-10

Last Posted Date: 2008-09-11

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 35

Registration Number: NCT00290004

Locations: 🇺🇸
USC Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Scripps Cancer Center, San Diego, California, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy